Neuromelanin-sensitive MRI as a biomarker for individualized deep brain stimulation in Parkinson's disease: Associations between substantia nigra imaging and therapeutic outcomes | Synapse
March 3, 2026
Neuromelanin-sensitive MRI as a biomarker for individualized deep brain stimulation in Parkinson's disease: Associations between substantia nigra imaging and therapeutic outcomes
Key Points
Successful neuromelanin-sensitive MRI predicts therapeutic outcomes in deep brain stimulation.
Key evidence shows that improvements in motor function and reduced symptoms correlate significantly with imaging results.
Observational analysis assessed 50 patients, revealing strong associations between substantia nigra imaging and functional outcomes.
Findings highlight the potential for tailoring deep brain stimulation based on individual neuromelanin biomarkers.